TuHURA Biosciences, Inc.
HURA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 33.3% and free cash flow fell 70.5%, each against the same quarter a year earlier.
Follow HURA
TuHURA Biosciences, Inc. (HURA) Altman Z-score
Altman Z-score, annual
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|
How the score is made up
There are no annual figures to work it out from.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| SPRB Spruce Biosciences, Inc. compare | 36.6× |
| NERV Minerva Neurosciences, Inc compare | 6.0× |
| SEER Seer, Inc. compare | −0.5× |
| FHTX Foghorn Therapeutics Inc. compare | −4.5× |
| ARMP Armata Pharmaceuticals, Inc. compare | −10.2× |
| NRXP NRx Pharmaceuticals, Inc. compare | −37.8× |
| ENGN enGene Therapeutics Inc compare | — |
| ABOS Acumen Pharmaceuticals, Inc. compare | — |
| HURA TuHURA Biosciences, Inc. | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets